Although the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis
(ERS-RA) is frequently used to estimate cardiovascular risk among rheumatoid arthritis
(RA) patients, it does not include plasma C-reactive protein (CRP) concentrations.
The study by Erre and colleagues revealed that a 20 mg/L increase in CRP concentrations
was correlated with a 1% increase in 10-year cardiovascular risk among RA patients
[
[1]
]. Their findings suggest that aggressive treatment aimed at reducing inflammation
may decrease cardiovascular risks.Abbreviations:
ACPA (anti-cyclic citrullinated peptide antibody), CRP (C-reactive protein), EM (extra-articular manifestation), ERS-RA (Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis), RA (rheumatoid arthritis), SCORE (Systemic Coronary Risk Evaluation)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.Eur J Intern Med. 2022; 104: 49-54https://doi.org/10.1016/j.ejim.2022.07.001
- Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis.Clin Rheumatol. 2009; 28: 767-775https://doi.org/10.1007/s10067-009-1145-8
- Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk.Eur J Intern Med. 2009; 20: 348-354https://doi.org/10.1016/j.ejim.2008.09.005
- Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile?.J Cardiovasc Dis Res. 2013; 4: 102-106https://doi.org/10.1016/j.jcdr.2012.09.003
- Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.Arthritis Rheumatol. 2009; 61: 419-424https://doi.org/10.1002/art.24390
- Rheumatoid arthritis patients "al nostro cuore".Eur J Intern Med. 2022; 96: 46-48https://doi.org/10.1016/j.ejim.2021.12.006
- Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the cardiovascular obesity and rheumatic diSease (CORDIS) study group.Eur J Intern Med. 2022; 96: 60-65https://doi.org/10.1016/j.ejim.2021.10.001
Article info
Publication history
Published online: December 01, 2022
Accepted:
November 28,
2022
Received in revised form:
November 25,
2022
Received:
November 4,
2022
Publication stage
In Press Corrected ProofFootnotes
☆Funding: None.
☆Conflicts of Interest: None.
☆Authorship: All authors verify contribution to the production and writing of this manuscript.
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
